{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-029775","form_type":"8-K","ticker":"GCTK","cik":"0001506983","company_name":"Glucotrack, Inc.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.301597+00:00","generated_at":"2026-05-31T14:21:04.851692+00:00","sec_items":["1.01","2.03","3.02","5.02","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Glucotrack secures $4M convertible note from leading shareholder for CBGM clinical trial","bullets":["$4M secured convertible note from John Ballantyne at 8% interest, due in 12 months or upon sale event.","Note conversion requires stockholder approval; conversion at closing price or auto-convert if stock exceeds $5.","Three warrants issued: 2.13M shares at $1.875, 1.52M at $2.625, 1.19M at $3.375; exercisable after 12 months for 10 years.","Directors Shimon Rapp and Andrew Sycoff resigned July 29, no dispute.","Proceeds to fund first-in-human clinical trial of implantable continuous blood glucose monitor."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-029775","json":"https://secwatch.observer/filing/0001493152-24-029775.json","markdown":"https://secwatch.observer/filing/0001493152-24-029775.md","text":"https://secwatch.observer/filing/0001493152-24-029775.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/0001493152-24-029775-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:21:04.851692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d72f6201a","claim":"Shimon Rapp resigned as Director at Glucotrack, Inc..","evidence_excerpt":"On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/0001493152-24-029775-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"97a3b2d942","claim":"Andrew Sycoff resigned as Director at Glucotrack, Inc..","evidence_excerpt":"On July 29, 2024, Shimon Rapp and Andrew Sycoff resigned from the board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315224029775/0001493152-24-029775-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}